Document is current
Any future updates will be listed below
-
Authors
Molière, Sébastien
Lodi, Massimo
Leblanc, Suzanne
Gressel, Anne
Mathelin, Carole
Alpy, Fabien
Chenard, Marie-Pierre
Tomasetto, Catherine
-
Funding
Funding for this research was provided by:
IdEx Unistra (ANR-10-IDEX-0002, ANR-10-IDEX-0002, ANR-10-IDEX-0002)
EUR IMCBio (ANR-17-EURE-0023, ANR-17-EURE-0023, ANR-17-EURE-0023)
Ligue Contre le Cancer (Ligue Contre le Cancer, Ligue Contre le Cancer, Ligue Contre le Cancer)
SEVE (SEVE (Sein et Vie), SEVE (Sein et Vie), SEVE (Sein et Vie))
Alsace Contre le Cancer (Alsace Contre le Cancer, Alsace Contre le Cancer, Alsace Contre le Cancer)
- License Information
-
More Information
Article History
Received: 4 November 2023
Accepted: 13 February 2024
First Online: 4 March 2024
Declarations
:
: Breast cancer tumor specimens were sourced from the “Centre de Ressources Biologiques” (CRB) of the “Hôpitaux Universitaires de Strasbourg” (#1970-390-v0). These samples were all obtained from patients treated at the Strasbourg University Hospital. The study received approval from the Local Ethics Committee (Comité de Protection des Personnes Est IV). The research was part of the cohort study named SENOMETRY (ClinicalTrials.gov Identifier: NCT02810093), which has received the favorable opinion of the Committee for the Protection of Persons (CPP) Est IV in 2016, the Institutional Review Board for the Strasbourg University Hospital. The CRB’s database is registered with the French Commission Nationale Informatique et Liberté, under the identifier 1187586. All samples and their associated medical data were anonymized for research purposes. All participants provided their informed consent for inclusion in the study.
: Not applicable.
: The authors declare no conflict of interest. The financial sponsors played no part in the study's design, data collection, analysis, manuscript preparation, or decision to publish.
